Peptide-based in vivo siRNA delivery system

US9107957B2 · kind B2 · utility

Assignee

• Arrowhead Madison, Inc. · US

Inventors

• David B. Rozema · Madison, US
• David L. Lewis · Madison, US
• Darren H. Wakefield · Fitchburg, US
• Eric A. Kitas · Aesch, CH
• Philipp Hadwiger · Kulmbach, DE
• Jon Wolff · Madison, US
• Ingo Röhl · Memmelsdorf, DE
• Peter Mohr · Basel, CH
• Torsten Hoffmann · Weil am Rhein, DE
• Kerstin Jahn-Hofmann · Neu-Isenburg, DE
• Hans Martin Mueller · Weilheim, DE
• Günther Ott · Bayreuth, DE
• Andrei V. Blokhin · Fitchburg, US
• Jonathan D. Benson · Stoughton, US
• Jeffrey C. Carlson · Madison, US

Key dates

• Filing date: Jun 25, 2013
• Grant date: Aug 18, 2015
• Expiry date: Aug 30, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.